{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T14:34:27Z","timestamp":1791470067241,"version":"4.3.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T00:00:00Z","timestamp":1721001600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS J"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Measurement of anti-drug antibodies (ADA) to assess the incidence of ADA in a clinical trial is a critical step in immunogenicity assessment during the development of a protein therapeutic. We developed novel graphical approaches to illustrate clinical trial ADA data for the PD-L1 inhibitor atezolizumab (Tecentriq) that included a systematic analysis of the impact of the timing of ADA sampling and ADA assay drug tolerance on reported ADA incidence. We found that approaches used across the industry for ADA incidence analysis provide a limited view of immunogenicity in oncology studies, where ADA detection may be confounded by both drug dosage and patient attrition. Moreover, these approaches can miss important temporal information about the immune response. Our results demonstrated that the methodology of ADA assessment for the atezolizumab program was specifically designed to capture most ADA responses to ensure accurate reporting of ADA incidence. We further showed that the use of sparse sampling and\/or ADA test methods with insufficient drug tolerance may result in a significant underreporting of ADA incidence. We conclude that the comparison of ADA incidence between different drugs can be highly misleading and that a test method with appropriate sensitivity in the presence of the drug and a clinical sampling scheme that is aligned with ADA responses to a drug is required to accurately report ADA incidence.<\/jats:p>\n          <jats:p>\n            <jats:bold>Graphical Abstract<\/jats:bold>\n          <\/jats:p>","DOI":"10.1208\/s12248-024-00954-2","type":"journal-article","created":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T19:12:48Z","timestamp":1721070768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Immunogenicity of Atezolizumab: Influence of Testing Method and Sampling Frequency on Reported Anti-drug Antibody Incidence Rates"],"prefix":"10.1208","volume":"26","author":[{"given":"Maxime","family":"Usdin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie","family":"Quarmby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7457-6411","authenticated-orcid":false,"given":"James","family":"Zanghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Coen","family":"Bernaards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Laxamana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Swanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patty","family":"Siguenza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,15]]},"reference":[{"issue":"10","key":"954_CR1","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1634\/theoncologist.2016-0061","volume":"21","author":"EMJ van Brummelen","year":"2016","unstructured":"van Brummelen EMJ, Ros W, Wolbink G, Beijnen JH, Schellens JHM. Antidrug antibody formation in oncology: clinical relevance and challenges. Oncologist. 2016;21(10):1260\u20138.","journal-title":"Oncologist"},{"key":"954_CR2","unstructured":"Research C for DE and. Immunogenicity Assessment for Therapeutic Protein Products [Internet]. FDA; 2020 [cited 2024 Feb 2]. Available from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-assessment-therapeutic-protein-products."},{"key":"954_CR3","unstructured":"Research C for DE and. Immunogenicity Testing of Therapeutic Protein Products \u2014Developing and Validating Assays for Anti-Drug Antibody Detection [Internet]. FDA; 2020 [cited 2024 Feb 2]. Available from:  https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/immunogenicity-testing-therapeutic-protein-products-developing-and-validating-assays-anti-drug."},{"issue":"1\u20132","key":"954_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2004.06.002","volume":"289","author":"AR Mire-Sluis","year":"2004","unstructured":"Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, et al. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods. 2004;289(1\u20132):1\u201316.","journal-title":"J Immunol Methods"},{"issue":"1\u20132","key":"954_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jim.2008.01.001","volume":"333","author":"E Koren","year":"2008","unstructured":"Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, et al. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods. 2008;333(1\u20132):1\u20139.","journal-title":"J Immunol Methods"},{"issue":"4","key":"954_CR6","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1208\/s12248-014-9599-2","volume":"16","author":"G Shankar","year":"2014","unstructured":"Shankar G, Arkin S, Cocea L, Devanarayan V, Kirshner S, Kromminga A, et al. Assessment and reporting of the clinical immunogenicity of therapeutic proteins and peptides-harmonized terminology and tactical recommendations. AAPS J. 2014;16(4):658\u201373.","journal-title":"AAPS J"},{"key":"954_CR7","unstructured":"Immunogenicity assessment of biotechnology-derived therapeutic proteins - Scientific guideline | European Medicines Agency [Internet]. [cited 2024 Feb 2]. https:\/\/www.ema.europa.eu\/en\/immunogenicity-assessment-biotechnology-derived-therapeutic-proteins-scientific-guideline."},{"key":"954_CR8","unstructured":"genentech-medinfo [Internet]. [cited 2024 Feb 2]. Tecentriq\u00ae (atezolizumab) | Genentech Prescribing & Product Information. https:\/\/www.genentech-medinfo.com\/our-products\/oncology\/tecentriq.html."},{"issue":"1","key":"954_CR9","first-page":"9","volume":"13","author":"S Narayanan","year":"2001","unstructured":"Narayanan S, Guder WG. Preanalytical variables and their influence on the quality of laboratory results. EJIFCC. 2001;13(1):9\u201312.","journal-title":"EJIFCC"},{"issue":"10066","key":"954_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/S0140-6736(16)32517-X","volume":"389","author":"A Rittmeyer","year":"2017","unstructured":"Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. Atezolizumab versus Docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet Lond Engl. 2017;389(10066):255\u201365.","journal-title":"Lancet Lond Engl"},{"issue":"2","key":"954_CR11","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/cpt.587","volume":"102","author":"M Stroh","year":"2017","unstructured":"Stroh M, Winter H, Marchand M, Claret L, Eppler S, Ruppel J, et al. Clinical pharmacokinetics and pharmacodynamics of Atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther. 2017;102(2):305\u201312.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"954_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1111\/cts.13127","volume":"15","author":"B Wu","year":"2022","unstructured":"Wu B, Sternheim N, Agarwal P, Suchomel J, Vadhavkar S, Bruno R, et al. Evaluation of atezolizumab immunogenicity: clinical pharmacology (part 1). Clin Transl Sci. 2022;15(1):130\u201340.","journal-title":"Clin Transl Sci"},{"key":"954_CR13","unstructured":"Allelic Variation in HLA-DRB1 is Associated with Development of Anti-Drug Antibodies in Cancer Patients Treated with Atezolizumab that are Neutralizing in Vitro - Google Search [Internet]. [cited 2024 Feb 2]. Available from:\u00a0https:\/\/www.google.com\/search?q=Allelic+Variation+in+HLA-DRB1+is+Associated+with+Development+of+Anti-Drug+Antibodies+in+Cancer+Patients+Treated+with+Atezolizumab+that+are+Neutralizing+in+Vitro&rlz=1C5GCEA_enUS1088US1088&oq=Allelic+Variation+in+HLA-DRB1+is+Associated+with+Development+of+Anti-Drug+Antibodies+in+Cancer+Patients+Treated+with+Atezolizumab+that+are+Neutralizing+in+Vitro&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIGCAEQRRhA0gEHMTE0ajBqMagCALACAA&sourceid=chrome&ie=UTF-8."},{"issue":"1","key":"954_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1111\/cts.13149","volume":"15","author":"S Peters","year":"2022","unstructured":"Peters S, Galle PR, Bernaards CA, Ballinger M, Bruno R, Quarmby V, et al. Evaluation of atezolizumab immunogenicity: efficacy and safety (part 2). Clin Transl Sci. 2022;15(1):141\u201357.","journal-title":"Clin Transl Sci"},{"key":"954_CR15","doi-asserted-by":"publisher","unstructured":"Presence and impact of antidrug antibodies (ADAs) to tremelimumab (T) or durvalumab (D) in the phase 3 HIMALAYA study of unresectable hepatocellular carcinoma (uHCC). | Journal of Clinical Oncology [Internet]. [cited 2024 Feb 2]. Available from: https:\/\/doi.org\/10.1200\/JCO.2023.41.4_suppl.551.","DOI":"10.1200\/JCO.2023.41.4_suppl.551"},{"key":"954_CR16","doi-asserted-by":"publisher","unstructured":"Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. | NEJM [Internet]. [cited 2024 Feb 2]. https:\/\/www.nejm.org\/doi\/full\/https:\/\/doi.org\/10.1056\/NEJMoa2002788.","DOI":"10.1056\/NEJMoa2002788"},{"issue":"1","key":"954_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1208\/s12248-021-00649-y","volume":"24","author":"H Myler","year":"2022","unstructured":"Myler H, Pedras-Vasconcelos J, Phillips K, Hottenstein CS, Chamberlain P, Devanaryan V, et al. Anti-drug antibody validation testing and reporting harmonization. AAPS J. 2022;24(1):4.","journal-title":"AAPS J"},{"issue":"1","key":"954_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1186\/s40425-019-0663-4","volume":"7","author":"MJH van Vugt","year":"2019","unstructured":"van Vugt MJH, Stone JA, De Greef RHJMM, Snyder ES, Lipka L, Turner DC, et al. Immunogenicity of pembrolizumab in patients with advanced tumors. J Immunother Cancer. 2019;7(1):212.","journal-title":"J Immunother Cancer"},{"issue":"4","key":"954_CR19","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.apjon.2021.12.015","volume":"9","author":"J Kim","year":"2022","unstructured":"Kim J, Kim MG, Lim KM. Participation in and withdrawal from cancer clinical trials: a survey of clinical research coordinators. Asia-Pac J Oncol Nurs. 2022;9(4):197\u2013201.","journal-title":"Asia-Pac J Oncol Nurs"},{"issue":"6suppl","key":"954_CR20","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1200\/JCO.2023.41.6_suppl.105","volume":"41","author":"J Lloyd","year":"2023","unstructured":"Lloyd J, Nordblad B, Sahu KKK, Swami U, Phunrab TK, Batten JA, et al. Investigating documented reasons for withdrawal from clinical trials for patients with advanced prostate cancer (PCa). J Clin Oncol. 2023;41(6suppl):105\u2013105.","journal-title":"J Clin Oncol"},{"issue":"5","key":"954_CR21","first-page":"533","volume":"15","author":"M Alonso-Garc\u00eda","year":"2022","unstructured":"Alonso-Garc\u00eda M, S\u00e1nchez-Gastaldo A, Mu\u00f1oz-Fuentes MA, Molina-Pinelo S, Boyero L, Benedetti JC, et al. Real-world analysis of Nivolumab and Atezolizumab efficacy in previously treated patients with advanced non-small cell lung cancer. Pharm Basel Switz. 2022;15(5):533.","journal-title":"Pharm Basel Switz"},{"issue":"3","key":"954_CR22","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1002\/jcph.818","volume":"57","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Statkevich P, Bajaj G, Feng Y, Saeger S, Desai DD, et al. Evaluation of immunogenicity of nivolumab monotherapy and its clinical relevance in patients with metastatic solid tumors. J Clin Pharmacol. 2017;57(3):394\u2013400.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"954_CR23","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1158\/1078-0432.CCR-19-2337","volume":"26","author":"D Enrico","year":"2020","unstructured":"Enrico D, Paci A, Chaput N, Karamouza E, Besse B. Antidrug antibodies against immune checkpoint blockers: impairment of drug efficacy or indication of Immune activation? Clin Cancer Res off J Am Assoc Cancer Res. 2020;26(4):787\u201392.","journal-title":"Clin Cancer Res off J Am Assoc Cancer Res"},{"issue":"6","key":"954_CR24","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40259-021-00507-5","volume":"35","author":"SJ Bots","year":"2021","unstructured":"Bots SJ, Parker CE, Brandse JF, L\u00f6wenberg M, Feagan BG, Sandborn WJ, et al. Anti-drug antibody formation against biologic agents in inflammatory bowel disease: a systematic review and meta-analysis. BioDrugs. 2021;35(6):715\u201333.","journal-title":"BioDrugs"},{"issue":"1","key":"954_CR25","doi-asserted-by":"publisher","first-page":"e008266","DOI":"10.1136\/jitc-2023-008266","volume":"12","author":"P Galle","year":"2024","unstructured":"Galle P, Finn RS, Mitchell CR, Ndirangu K, Ramji Z, Redhead GS, et al. Treatment-emergent antidrug antibodies related to PD-1, PD-L1, or CTLA-4 inhibitors across tumor types: a systematic review. J Immunother Cancer. 2024;12(1):e008266.","journal-title":"J Immunother Cancer"}],"updated-by":[{"DOI":"10.1208\/s12248-025-01077-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T00:00:00Z","timestamp":1750377600000}}],"container-title":["The AAPS Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00954-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12248-024-00954-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12248-024-00954-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,20]],"date-time":"2025-06-20T18:28:30Z","timestamp":1750444110000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12248-024-00954-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,15]]},"references-count":25,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["954"],"URL":"https:\/\/doi.org\/10.1208\/s12248-024-00954-2","relation":{},"ISSN":["1550-7416"],"issn-type":[{"value":"1550-7416","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,15]]},"assertion":[{"value":"5 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to switch Figure 6a and Figure 6b graphs.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1208\/s12248-025-01077-y","URL":"https:\/\/doi.org\/10.1208\/s12248-025-01077-y","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors are former (VQ) or current (MU, JZ, CB, LL, JL, BW, SS, YS, PS) employees of Genentech, a wholly-owned member of the Roche Group, and own\/owned Roche stock and\/or options at the time of their employment.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"84"}}